#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Development and Benefits of Intestinal Gel LECIG for Patients with Parkinson's Disease

Patients with advanced Parkinson's disease, for whom the current regimen of orally and transdermally administered medications is insufficient for symptom relief, now have a new treatment option. It involves the continuous administration of an intestinal gel that combines three effective antiparkinsonian drugs.
Source: Parkinson's Disease 10. 3. 2023

News Intestinal Gel LECIG in the Treatment of Advanced Parkinson's Disease in Real Practice

A recently published study presents the first experiences with an intestinal gel containing a triple combination of antiparkinsonian drugs and dosed via an infusion pump through percutaneous endoscopic gastrostomy extended into the jejunum in the treatment of advanced Parkinson's disease.
Source: Parkinson's Disease 10. 3. 2023

News Efficacy of Hyaluronic Acid Eye Drops in the Treatment of Dry Eye Syndrome –⁠ Results of a Meta-Analysis

Dry eye syndrome affects 5–30% of individuals over the age of 50. The beneficial effect of hyaluronic acid on the symptoms of this condition has been well described in both preclinical and clinical studies, and it has been shown that its topical application increases the secretion of water and mucin on the surface of the eye. The meta-analysis presented below focused on the efficacy of eye drops containing hyaluronic acid in the treatment of dry eye syndrome.
Source: Ophthalmologic Diseases 13. 3. 2023

News Prof. Petra Lišková: Prevention of Dry Eye Syndrome is Difficult but Not Impossible

Dry eye syndrome is one of the most common ophthalmological problems, and its incidence is rising. Ophthalmologist Prof. MUDr. Petra Lišková, Ph.D., from the Clinic of Pediatrics and Hereditary Metabolic Disorders of the First Faculty of Medicine, Charles University, and University Hospital in Prague, explains how these difficulties arise and why patients should visit an eye doctor rather than relying solely on self-treatment.
Source: Ophthalmologic Diseases 13. 3. 2023

News Current View on Obstacles in Proper Use of Antibiotics and the Role of Biomarkers in Infection Diagnosis

In the fight against antibiotic resistance, principles for the proper use of antibiotics (ATB) have been introduced globally. The following overview briefly describes the obstacles in leading rational antibiotic therapy and considers the use and benefits of biomarkers.
Source: Anti-Infectives 13. 4. 2023

News Longer survival without liver transplant in patients with PBC treated with OCA?

Obeticholic acid (OCA) is a second-line treatment for patients with primary biliary cholangitis (PBC) who have an inadequate response to ursodeoxycholic acid (UDCA) or intolerance to it. The study presented below, the results of which were recently published, examined the effectiveness of OCA in reducing cholestatic enzymes as well as the length of survival without liver transplant in patients with PBC.
Source: Primary Biliary Cholangitis 20. 3. 2023

News Results of Long-Term Follow-Up of Patients with Prostate Adenocarcinoma After Radiotherapy with Short-Term Androgen Deprivation

Adding short-term androgen deprivation to radiotherapy improved overall survival, disease-specific mortality, and the incidence of distant metastases in men diagnosed with prostate adenocarcinoma. Subsequent analysis investigated whether the beneficial effect of androgen deprivation is long-lasting.
Source: Oncological Treatment 21. 3. 2023

News H₂FPEF Score for Estimating the Probability of Heart Failure with Preserved Ejection Fraction in Persons with Unexplained Dyspnea

The simple, validated H₂FPEF scoring system based on clinical and echocardiographic parameters, developed by experts from the Mayo Clinic, allows the differentiation of heart failure with preserved ejection fraction (HFpEF) from dyspnea of other etiologies and helps decide whether further examinations are necessary. The score can be calculated online and in the Czech language.
Source: Heart Failure 23. 3. 2023

News Liposomal Ozonated Oil in the Treatment of Eye Infections

Liposomal ozonated oil is a new ocular antiseptic with antibacterial, anti-inflammatory, and regenerative properties, making it suitable for the prevention and treatment of eye infections and as an adjuvant in wound healing. In June 2022, Spanish authors published a review summarizing findings on the mechanism of action and results of preclinical and clinical studies with ozonated oil in the treatment of eye infections and in the regeneration of the ocular surface. It also highlights the benefits of ozonated oil compared to conventional antiseptics such as povidone-iodine and chlorhexidine.
Source: Treatment of Glaucoma 24. 3. 2023

News INFOGRAPHIC: Determining the Target Intraocular Pressure in Glaucoma Therapy

The goal of glaucoma treatment is to preserve the visual field and the quality of life of patients. Currently, the only approach to preserving the visual field of patients is to reduce intraocular pressure (IOP). Its target value should be determined for each patient with consideration of individual risk factors. The following comprehensive infographic shows which factors should be considered according to the current recommendations of the European Glaucoma Society (EGS).
Source: Treatment of Glaucoma 14. 7. 2023

News Efficacy of Bisoprolol in Patients After Acute MI with LV Systolic Dysfunction

What impact does one year of bisoprolol use have in real-world practice on heart rate, left ventricular ejection fraction (LVEF), glycated hemoglobin (HbA1c) levels, or lipid profile in patients after acute myocardial infarction (AMI) with left ventricular systolic dysfunction (LVSD)? This was investigated by the authors of a study whose results were published last year.
Source: Cardiovascular Continuum 27. 3. 2023

News Beta-blockers in the treatment of chronic heart failure: How did the analysis of the effects of 4 drugs in 26 studies turn out?

As a cornerstone of therapy for chronic heart failure with reduced ejection fraction (HFrEF), it is recommended to start treatment with a very low dose of beta-blockers (BB) and titrate it to the maximum tolerated dose. However, it remains unclear whether one BB is superior to others. For this reason, a comprehensive pooled analysis of the efficacy and safety of bisoprolol, carvedilol, nebivolol, and metoprolol in 26 studies, including 14 randomized controlled and 12 observational, was recently published.
Source: Cardiovascular Continuum 28. 3. 2023

News Cardiovascular Interventions with Continued Therapy with Dabigatran −⁠ Insights from the GLORIA-AF Study

An analysis using data from an international registry of patients with newly diagnosed atrial fibrillation evaluated the safety and efficacy of continued therapy with dabigatran during cardioversion or atrial fibrillation ablation, pacemaker implantation, and coronary angiography with possible stent implantation.
Source: Anticoagulant Treatment 12. 1. 2023

News Long-term Safety of Dupilumab in Adult Patients with Moderate to Severe Atopic Dermatitis

Moderate to severe atopic dermatitis (AD) often requires systemic therapy. The long-term safety of dupilumab in patients with this condition was evaluated in an open-label extension (OLE) of the LIBERTY AD study, the results of which were recently published.
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 24. 1. 2023

News Relationship Between Mortality and Use of Statins or RAAS Inhibitors After Aortic Valve Replacement

The impact of prescribed medication after transcatheter aortic valve replacement (TAVR) has not been precisely assessed to date. A recently published retrospective analysis of clinical practice data from patients who underwent TAVR aimed to assess the potential benefit of using statins and renin-angiotensin-aldosterone system (RAAS) inhibitors.
Source: Sartans in the Treatment of Hypertension 16. 3. 2023

1 44 45 46 47 48 667
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#